ANAPTYSBIO, INC ANAB
Nasdaq · XNAS · stock · Pharmaceutical Preparations
Chart by TradingView
5/9
Piotroski F — financial health
-0.3
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | $234.6M | -$13.2M | — | $19.6M | $37.2M |
| 2024 | $91.3M | -$145.2M | — | -$135.7M | $70.9M |
| 2023 | $17.2M | -$163.6M | — | -$121.6M | $88.1M |
| 2022 | $10.3M | -$128.7M | — | -$74.0M | $262.1M |
| 2021 | $63.2M | -$57.8M | — | -$47.3M | $356.4M |
| 2020 | $75.0M | -$19.9M | — | -$14.7M | $396.7M |
Recent insider activity (Form 4)
| Insider | Role | Date | Action | Shares | Price |
|---|---|---|---|---|---|
| Schmid John P. | director | 2026-06-15 | Option exercise | 6,030 | — |
| RENTON HOLLINGS | director | 2026-06-15 | Option exercise | 6,030 | — |
| Orwin John A | director | 2026-06-15 | Option exercise | 6,030 | — |
Why these scores methodology →
Piotroski F-score: 5/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: -0.3 (distress)
- Working capital / assets 0.855
- Retained earnings / assets -2.12
- EBIT / assets 0.131
- Equity / liabilities 0.114
Source: SEC EDGAR filings · CIK 0001370053 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.